Published in J Hepatol on April 01, 1997
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection. World J Gastroenterol (2014) 0.86
Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencing. World J Gastroenterol (2012) 0.82
HBV polymerase overexpression due to large core gene deletion enhances hepatoma cell growth by binding inhibition of microRNA-100. Oncotarget (2016) 0.78
Increase in primary liver cancer in the UK, 1979-94. Lancet (1997) 6.15
Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science (1996) 5.55
Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31
Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet (1989) 5.16
Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A (1996) 4.02
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 4.01
Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med (1995) 3.54
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut (2001) 3.45
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology (1998) 3.31
Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med (1981) 3.17
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet (2000) 2.58
The induction of tolerance to a soluble protein antigen by oral administration. Immunology (1974) 2.50
Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology (1983) 2.36
Is primary biliary cirrhosis an immune complex disease? Lancet (1977) 2.15
Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology (1989) 2.15
Role of the liver in controlling the immunogenicity of commensal bacteria in the gut. Lancet (1973) 2.15
Isolation of Chlamydia trachomatis from Bartholin's ducts. Br J Vener Dis (1978) 2.13
Detection of hepatitis B virus DNA directly in human serum by a simplified molecular hybridization test: comparison to HBeAg/anti-HBe status in HBsAg carriers. Hepatology (1983) 2.10
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology (1994) 2.00
Immune complexes in acute and chronic liver disease. Clin Exp Immunol (1978) 1.93
Evidence for a cerebral effect of the hepatitis C virus. Lancet (2001) 1.90
Incidence and clinical significance of e antigen and antibody in acute and chronic liver disease. Lancet (1975) 1.90
Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun (2003) 1.88
Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: three years experience in a London hospital. Q J Med (1989) 1.88
The detection of HBV-DNA in serum by molecular hybridisation: a more sensitive method for the detection of complete HBV particles. J Med Virol (1982) 1.81
Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet (1997) 1.71
Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders. Gut (1981) 1.67
Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A (1991) 1.64
Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis. Lancet (1980) 1.61
Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology (2001) 1.61
Quantitative aspects of chlamydial infection of the cervix. Br J Vener Dis (1980) 1.51
Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess (2006) 1.50
Is mitochondrial antibody diagnostic of primary biliary cirrhosis? Gut (1981) 1.50
Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet (1984) 1.49
Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest (1992) 1.48
Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology (1997) 1.47
Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology (1985) 1.45
Detection of serum HBV-DNA by molecular hybridisation. Correlation with HBeAg/anti-HBe status, racial origin, liver histology and hepatocellular carcinoma. J Hepatol (1985) 1.43
Peripheral blood lymphocyte populations in chronic liver disease. Clin Exp Immunol (1976) 1.43
Pseudomembranous colitis following clarithromycin therapy. Eur J Gastroenterol Hepatol (1995) 1.40
Significance of delta agent infection in chronic hepatitis B virus infection: a study in British carriers. Gut (1983) 1.40
Recent advances in the molecular biology of hepatitis B virus: mutant virus and the host response. Gut (1993) 1.39
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol (2001) 1.39
Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology (1981) 1.38
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology (2001) 1.38
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther (2000) 1.37
Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft-versus-host disease. Lancet (1980) 1.36
Hepatitis B virus and HLA antigen display in the liver during chronic hepatitis B virus infection. Hepatology (1982) 1.36
Double-stranded DNA-binding capacity of serum in acute and chronic liver disease. Clin Exp Immunol (1976) 1.35
Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology (1998) 1.33
Cytotoxic T-cell responses to the nucleocapsid proteins of HBV in chronic hepatitis. Evidence that antibody modulation may cause protracted infection. J Hepatol (1987) 1.33
Protection against hepatitis B virus infection by immunization with hepatitis B core antigen. Gastroenterology (1985) 1.32
HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection. Hepatology (1986) 1.31
Restoration of holoceruloplasmin synthesis in LEC rat after infusion of recombinant adenovirus bearing WND cDNA. J Biol Chem (1998) 1.30
Genetic variation in hepatitis B virus. Gastroenterology (1992) 1.29
Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet (1986) 1.29
Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology (1991) 1.29
HLA-B8, immunoglobulins, and antibody responses in alcohol-related liver disease. J Clin Pathol (1980) 1.28
Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology (1996) 1.27
Persistence of chlamydial infection after treatment for neonatal conjunctivitis. Arch Dis Child (1981) 1.26
A rapid one-step radiometric assay for hepatitis B surface antigen utilizing monoclonal antibodies. J Immunol Methods (1982) 1.26
Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut (2005) 1.26
An analysis of the composition of the inflammatory infiltrate in autoimmune and hepatitis B virus-induced chronic liver disease. Hepatology (1983) 1.25
Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. J Hepatol (2001) 1.25
Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ (1997) 1.24
The immune response in hepatic cirrhosis: animal and human studies. Proc R Soc Med (1977) 1.23
Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat (2008) 1.22
Seroprevalence of hepatitis C virus nucleocapsid antibodies in patients with cryptogenic chronic liver disease. Hepatology (1992) 1.22
Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. N Engl J Med (1979) 1.22
Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J Infect Dis (1993) 1.22
Inducer and suppressor T-cells in hepatitis B virus-induced liver disease. Hepatology (1982) 1.20
Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther (2001) 1.20
Hepatitis-associated antigen in chronic liver disease. Lancet (1970) 1.19
The mechanism of replication of hepatitis B virus: evidence of asymmetric replication of the two DNA strands. J Med Virol (1984) 1.18
Staurosporine-induced apoptosis in cardiomyocytes: A potential role of caspase-3. J Mol Cell Cardiol (1998) 1.17
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol (2000) 1.16
High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol (1985) 1.15
HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine. Br Med J (1978) 1.15
Antiviral therapy in hepatitis B infection. Br Med Bull (1985) 1.15
Oral infections with Candida albicans. Scott Med J (1973) 1.15
Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat (2009) 1.14
A unique insertion in the S gene of surface antigen--negative hepatitis B virus Chinese carriers. Hepatology (1995) 1.14
Acute type A, B, and non-A, non-B hepatitis in a hospital population in London: clinical and epidemiological features. Gut (1983) 1.13
Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. J Med Virol (2000) 1.13
Lymphocyte populations in liver biopsy specimens from patients with chronic liver disease. Gut (1977) 1.13